Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916870 | 1.00 | AR (0.66) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL9023047 | 1.00 | AR (0.66) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL9022365 | 0.96 | AR (0.62) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL9022360 | 0.96 | AR (0.62) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL9441224 | 0.95 | AR (0.61) | ARSRD5A2SRD5A1 | |
| SCHEMBL9441221 | 0.95 | AR (0.61) | ARSRD5A2SRD5A1 | |
| SCHEMBL9022656 | 0.94 | AR (0.59) | ARSRD5A2SRD5A1 | |
| SCHEMBL5212131 | 0.92 | AR (0.65) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL5211043 | 0.92 | AR (0.65) | ARSRD5A2SRD5A1KCNH2 | |
| SCHEMBL7080804 | 0.92 | AR (0.65) | ARSRD5A2SRD5A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-0859761-A4 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0859761-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997010217-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO., INC. (US) | 1997-03-20 | — | — | WO | claimed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | claimed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | claimed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | AR 22/4885SRD5A2 26/4885SRD5A1 17/4885 |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | AR 22/4885SRD5A2 26/4885SRD5A1 17/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | AR 12/4885SRD5A2 4/4885SRD5A1 10/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | AR 34/4885SRD5A2 53/4885SRD5A1 37/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | AR 12/4885SRD5A2 4/4885SRD5A1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.